雄激素受体在乳腺基底细胞样癌中的表达及意义  

Expression of androgen receptor in basal like breast carcinoma and its significance

作　　者：曲桂梅[1] 郎志强[1] 姚卫东[1] 于国华[1] 封小丽[1] 

机构地区：[1]烟台市毓璜顶医院病理科,山东烟台264000

出　　处：《诊断病理学杂志》2008年第6期485-487,共3页Chinese Journal of Diagnostic Pathology

摘　　要：目的探讨雄激素受体在乳腺基底细胞样癌(BLBC)中的表达及意义。方法应用组织芯片及免疫组化SP法检测雄激素受体(AR)、雌激素受体(ER)、孕激素受体(PR)及HER2的表达,并结合预后相关因素进行统计学分析。结果AR的阴性表达率为71.07%(86/121),其阴性表达与年龄>50岁、肿瘤高级别、直径>2 cm、淋巴结转移、ER和PR阴性明显相关(P<0.05)。AR的阳性表达率为11.57%(14/121),这些病例呈AR+/ER-/PR-。结论激素受体的阴性表达提示BLBC患者的预后较差。部分病例AR的阳性表达可能有助于探索对ER、PR阴性的BLBC患者实施新的治疗方案。Purpose To investigate the expression of androgen receptor in basal like breast carcinoma and to explore its significance. Methods Expression of AR, ER, PR and HER2 was detected by S-P immunohistochemical staining using tissue microarray. The relationship with the prognostic factors was analyzed. Results 71.07% BLBC showed negative staining for AR. AR negativity showed a significant relation to age of older than 50 years old, high histological grades, size of lager than 1.5 cm, matastasis of lymph nodes and negative expression of ER and PR （ P 〈 0.05）. 11.57 % （ 14/121 ） cases showed positive expression of AR and negative expression of ER and PR. Conclusion The negative immunostaining of hormone receptor indicates a worse prognosis. The positive expression of AR may be useful to explore new therapeutic strategies for ER and PR negative BLBC patients.

关 键 词：雄激素受体 乳腺基底细胞样癌 组织芯片 

分 类 号：R737.9[医药卫生—肿瘤]